Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:BIVV's Cash-to-Debt is ranked lower than
67% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:BIVV: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BIVV' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.78  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.52
NAS:BIVV's Equity-to-Asset is ranked lower than
69% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:BIVV: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BIVV' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.73 Max: 0.81
Current: 0.52
0.5
0.81
Debt-to-EBITDA 0.11
NAS:BIVV's Debt-to-EBITDA is ranked higher than
90% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:BIVV: 0.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:BIVV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.11
Current: 0.11
0
0.11
Interest Coverage No Debt
NAS:BIVV's Interest Coverage is ranked higher than
50% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:BIVV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:BIVV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 7.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 37.74
NAS:BIVV's Operating Margin % is ranked higher than
95% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:BIVV: 37.74 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BIVV' s Operating Margin % Range Over the Past 10 Years
Min: -267.93  Med: 17.49 Max: 37.74
Current: 37.74
-267.93
37.74
Net Margin % 40.44
NAS:BIVV's Net Margin % is ranked higher than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:BIVV: 40.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:BIVV' s Net Margin % Range Over the Past 10 Years
Min: -268.08  Med: 19.38 Max: 49.54
Current: 40.44
-268.08
49.54
ROE % 74.37
NAS:BIVV's ROE % is ranked higher than
99% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:BIVV: 74.37 )
Ranked among companies with meaningful ROE % only.
NAS:BIVV' s ROE % Range Over the Past 10 Years
Min: -245.27  Med: 32.01 Max: 92.46
Current: 74.37
-245.27
92.46
ROA % 45.41
NAS:BIVV's ROA % is ranked higher than
99% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:BIVV: 45.41 )
Ranked among companies with meaningful ROA % only.
NAS:BIVV' s ROA % Range Over the Past 10 Years
Min: -191.45  Med: 25.49 Max: 72.81
Current: 45.41
-191.45
72.81
ROC (Joel Greenblatt) % 165.16
NAS:BIVV's ROC (Joel Greenblatt) % is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:BIVV: 165.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BIVV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -274.99  Med: 31.23 Max: 165.16
Current: 165.16
-274.99
165.16
GuruFocus has detected 1 Warning Sign with Bioverativ Inc NAS:BIVV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BIVV's 30-Y Financials

Financials (Next Earnings Date: 2018-01-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BIVV Guru Trades in Q4 2016

Vanguard Health Care Fund 1,920,902 sh (unchged)
Mario Gabelli 936 sh (unchged)
Murray Stahl 3,328 sh (unchged)
Richard Snow 96,181 sh (unchged)
John Paulson 26,100 sh (unchged)
HOTCHKIS & WILEY 143,400 sh (unchged)
Joel Greenblatt 120,156 sh (unchged)
First Eagle Investment 128,513 sh (unchged)
Ron Baron 3,313 sh (unchged)
Ronald Muhlenkamp 11,640 sh (unchged)
David Dreman 301 sh (unchged)
Ken Fisher 50,944 sh (unchged)
John Buckingham 8,467 sh (unchged)
PRIMECAP Management 7,792,194 sh (unchged)
John Hussman 175 sh (unchged)
Frank Sands 1,289,455 sh (unchged)
John Burbank 2,952 sh (unchged)
Eric Mindich 163,941 sh (unchged)
Mairs and Power 513 sh (unchged)
Jim Simons 353,748 sh (unchged)
Paul Tudor Jones 3,908 sh (unchged)
Steven Cohen 26,771 sh (unchged)
Jeff Auxier 12,653 sh (unchged)
Lee Ainslie 5,440 sh (unchged)
Andreas Halvorsen 959,406 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 83,250 sh (unchged)
» More
Q1 2017

BIVV Guru Trades in Q1 2017

Jeff Ubben 8,476,892 sh (New)
Columbia Wanger 473,000 sh (New)
Paul Tudor Jones 705,824 sh (+17961.00%)
Jeff Auxier 24,179 sh (+91.09%)
First Eagle Investment 157,035 sh (+22.19%)
Vanguard Health Care Fund Sold Out
Frank Sands Sold Out
Jim Simons Sold Out
John Burbank Sold Out
Mario Gabelli Sold Out
Mairs and Power Sold Out
Ken Fisher Sold Out
Steven Cohen Sold Out
John Paulson Sold Out
Murray Stahl Sold Out
HOTCHKIS & WILEY Sold Out
John Buckingham Sold Out
John Hussman Sold Out
Andreas Halvorsen Sold Out
Lee Ainslie Sold Out
Ron Baron Sold Out
David Dreman Sold Out
Eric Mindich Sold Out
PRIMECAP Management 7,741,094 sh (-0.66%)
Ronald Muhlenkamp 11,543 sh (-0.83%)
Joel Greenblatt 109,907 sh (-8.53%)
Richard Snow 13,850 sh (-85.60%)
Eaton Vance Worldwide Health Sciences Fund 77,284 sh (-7.17%)
» More
Q2 2017

BIVV Guru Trades in Q2 2017

Louis Moore Bacon 25,000 sh (New)
Joel Greenblatt 227,377 sh (+106.88%)
Columbia Wanger 589,054 sh (+24.54%)
Eaton Vance Worldwide Health Sciences Fund 134,621 sh (+74.19%)
Jeff Auxier 24,179 sh (unchged)
Paul Tudor Jones Sold Out
First Eagle Investment Sold Out
Richard Snow Sold Out
Ronald Muhlenkamp 11,531 sh (-0.10%)
PRIMECAP Management 7,699,738 sh (-0.53%)
Jeff Ubben 7,163,892 sh (-15.49%)
» More
Q3 2017

BIVV Guru Trades in Q3 2017

David Dreman 300 sh (New)
Paul Tudor Jones 203,015 sh (New)
Jim Simons 804,800 sh (New)
Steven Cohen 141,000 sh (New)
Joel Greenblatt 386,990 sh (+70.20%)
Columbia Wanger 609,942 sh (+3.55%)
Eaton Vance Worldwide Health Sciences Fund 134,621 sh (unchged)
Louis Moore Bacon Sold Out
Jeff Auxier 24,167 sh (-0.05%)
PRIMECAP Management 7,642,976 sh (-0.74%)
Ronald Muhlenkamp 11,137 sh (-3.42%)
Jeff Ubben 1,270,619 sh (-82.26%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIVV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Add 70.20%0.13%$54.78 - $63.72 $ 50.24-14%386,990
Ronald Muhlenkamp 2017-09-30 Reduce -3.42%0.01%$54.78 - $63.72 $ 50.24-14%11,137
David Dreman 2017-09-30 New Buy0.01%$54.78 - $63.72 $ 50.24-14%300
Joel Greenblatt 2017-06-30 Add 106.88%0.1%$51.9 - $62.57 $ 50.24-12%227,377
Ronald Muhlenkamp 2017-06-30 Reduce -0.10%$51.9 - $62.57 $ 50.24-12%11,531
First Eagle Investment 2017-06-30 Sold Out 0.02%$51.9 - $62.57 $ 50.24-12%0
First Eagle Investment 2017-03-31 Add 22.19%$41.82 - $54.46 $ 50.245%157,035
Joel Greenblatt 2017-03-31 Reduce -8.53%0.01%$41.82 - $54.46 $ 50.245%109,907
Ronald Muhlenkamp 2017-03-31 Reduce -0.83%$41.82 - $54.46 $ 50.245%11,543
Vanguard Health Care Fund 2017-03-31 Sold Out $41.82 - $54.46 $ 50.245%0
John Paulson 2017-03-31 Sold Out 0.01%$41.82 - $54.46 $ 50.245%0
Ron Baron 2017-03-31 Sold Out $41.82 - $54.46 $ 50.245%0
David Dreman 2017-03-31 Sold Out 0.01%$41.82 - $54.46 $ 50.245%0
HOTCHKIS & WILEY 2017-03-31 Sold Out 0.03%$41.82 - $54.46 $ 50.245%0
Mario Gabelli 2017-03-31 Sold Out $41.82 - $54.46 $ 50.245%0
Ken Fisher 2017-03-31 Sold Out $41.82 - $54.46 $ 50.245%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TSRO, NAS:BLUE, HKSE:02269, NAS:JUNO, NAS:NBIX, NAS:UTHR, NAS:IONS, XAMS:GLPG, XKRX:128940, NAS:TECH, NAS:PBYI, HKSE:01530, NAS:ALKS, SZSE:000661, NAS:ACAD, NAS:EXEL, SZSE:002007, NAS:JAZZ, OSTO:SOBI, NAS:FGEN » details
Traded in other countries:50B.Germany, BIVV.Mexico,
Headquarter Location:USA
Bioverativ Inc is a global biotechnology company which focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders.

Bioverativ Inc is a global biotechnology company based in the US. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. The company market two products, ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B respectively. The company operates its business in one operating segment, which is Discovering, researching, developing and commercializing innovative therapies for the treatment of hemophilia and other blood disorders.

Ratios

vs
industry
vs
history
PE Ratio 10.73
BIVV's PE Ratio is ranked higher than
82% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. BIVV: 10.73 )
Ranked among companies with meaningful PE Ratio only.
BIVV' s PE Ratio Range Over the Past 10 Years
Min: 10.73  Med: 13.4 Max: 15.05
Current: 10.73
10.73
15.05
Forward PE Ratio 16.47
BIVV's Forward PE Ratio is ranked higher than
63% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. BIVV: 16.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.73
BIVV's PE Ratio without NRI is ranked higher than
84% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. BIVV: 10.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIVV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.73  Med: 13.4 Max: 15.05
Current: 10.73
10.73
15.05
PB Ratio 7.23
BIVV's PB Ratio is ranked lower than
80% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BIVV: 7.23 )
Ranked among companies with meaningful PB Ratio only.
BIVV' s PB Ratio Range Over the Past 10 Years
Min: 7.23  Med: 9.36 Max: 10.87
Current: 7.23
7.23
10.87
PS Ratio 4.95
BIVV's PS Ratio is ranked higher than
66% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. BIVV: 4.95 )
Ranked among companies with meaningful PS Ratio only.
BIVV' s PS Ratio Range Over the Past 10 Years
Min: 4.95  Med: 6.11 Max: 6.74
Current: 4.95
4.95
6.74
Price-to-Free-Cash-Flow 12.69
BIVV's Price-to-Free-Cash-Flow is ranked higher than
72% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. BIVV: 12.69 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIVV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.68  Med: 17.26 Max: 20.17
Current: 12.69
12.68
20.17
Price-to-Operating-Cash-Flow 12.18
BIVV's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. BIVV: 12.18 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIVV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.18  Med: 16.3 Max: 17.91
Current: 12.18
12.18
17.91
EV-to-EBIT 12.63
BIVV's EV-to-EBIT is ranked higher than
62% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. BIVV: 12.63 )
Ranked among companies with meaningful EV-to-EBIT only.
BIVV' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.62  Med: 15.95 Max: 17.7
Current: 12.63
12.62
17.7
EV-to-EBITDA 11.86
BIVV's EV-to-EBITDA is ranked higher than
63% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. BIVV: 11.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIVV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.86  Med: 14.2 Max: 15.8
Current: 11.86
11.86
15.8
EV-to-Revenue 4.74
BIVV's EV-to-Revenue is ranked higher than
69% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. BIVV: 4.74 )
Ranked among companies with meaningful EV-to-Revenue only.
BIVV' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.1  Med: 5.8 Max: 6.5
Current: 4.74
5.1
6.5
Current Ratio 2.01
BIVV's Current Ratio is ranked lower than
73% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BIVV: 2.01 )
Ranked among companies with meaningful Current Ratio only.
BIVV' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 4.35 Max: 5.82
Current: 2.01
2.01
5.82
Quick Ratio 1.90
BIVV's Quick Ratio is ranked lower than
73% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. BIVV: 1.90 )
Ranked among companies with meaningful Quick Ratio only.
BIVV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.7 Max: 4.24
Current: 1.9
1.06
4.24
Days Inventory 193.95
BIVV's Days Inventory is ranked lower than
79% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. BIVV: 193.95 )
Ranked among companies with meaningful Days Inventory only.
BIVV' s Days Inventory Range Over the Past 10 Years
Min: 193.95  Med: 943 Max: 1488.29
Current: 193.95
193.95
1488.29
Days Sales Outstanding 65.81
BIVV's Days Sales Outstanding is ranked higher than
53% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. BIVV: 65.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIVV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.45  Med: 61.5 Max: 183.04
Current: 65.81
61.45
183.04
Days Payable 30.22
BIVV's Days Payable is ranked lower than
76% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. BIVV: 30.22 )
Ranked among companies with meaningful Days Payable only.
BIVV' s Days Payable Range Over the Past 10 Years
Min: 19.49  Med: 74.52 Max: 143.05
Current: 30.22
19.49
143.05

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.81
BIVV's Price-to-Median-PS-Value is ranked higher than
51% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BIVV: 0.81 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIVV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 1.01 Max: 1.04
Current: 0.81
0.81
1.04
Earnings Yield (Greenblatt) % 7.94
BIVV's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. BIVV: 7.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIVV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.6  Med: 6.3 Max: 7.94
Current: 7.94
5.6
7.94

More Statistics

Revenue (TTM) (Mil) $1,096.00
EPS (TTM) $ 4.69
Short Percentage of Float5.67%
52-Week Range $40.99 - 64.41
Shares Outstanding (Mil)108.20

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 877 984 938 977
EPS ($) 2.40 2.51 2.31 2.47
EPS without NRI ($) 2.40 2.51 2.31 2.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.77%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}